drugset
drugset / Trial / NCT03092102

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

NCT03092102 ↗

Phase 1 Completed 136 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects

Timeline

Start
2017-05-20
Primary completion
2019-02-25
Completion
2019-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC585 Small molecule — Oral

Indications

idiopathic pulmonary fibrosis